EcoDrugPlus

Equilibrative Nucleoside Transporter 1

Ensembl ID : ENSXMAG00000018265
Gene Symbol: LOC102234367
3 Cross references
209 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 2

Ensembl ID : ENSXMAG00000018390
Gene Symbol: ERBB2
3 Cross references
200 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 3

Ensembl ID : ENSXMAG00000001930
Gene Symbol: ERBB3
3 Cross references
211 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 4

Ensembl ID : ENSXMAG00000007866
Gene Symbol: ERBB4
3 Cross references
230 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 4

Ensembl ID : ENSXMAG00000016012
Gene Symbol: ERBB4
3 Cross references
47 Possible Orthologues:

Estrogen Receptor 1

Ensembl ID : ENSXMAG00000003084
Gene Symbol: ESR1
3 Cross references
215 Possible Orthologues:

Estrogen Receptor Beta-Like

Ensembl ID : ENSXMAG00000023811
Gene Symbol: LOC102221770
3 Cross references
208 Possible Orthologues:

Estrogen Receptor Beta-Like

Ensembl ID : ENSXMAG00000006136
Gene Symbol: LOC102232037
3 Cross references
198 Possible Orthologues:

Estrogen-Related Receptor Gamma

Ensembl ID : ENSXMAG00000017600
Gene Symbol: LOC102231299
3 Cross references
198 Possible Orthologues:

Exportin 1

Ensembl ID : ENSXMAG00000007353
Gene Symbol: XPO1
3 Cross references
213 Possible Orthologues:

Exportin 1

Ensembl ID : ENSXMAG00000005790
Gene Symbol: XPO1
3 Cross references
224 Possible Orthologues:

Farnesyl Diphosphate Synthase

Ensembl ID : ENSXMAG00000016139
Gene Symbol: FDPS
3 Cross references
266 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).